REPH - レクロ・ファ―マ （Recro Pharma Inc.） レクロ・ファ―マREPHのチャート
REPHの企業情報
| symbol | REPH |
|---|---|
| 会社名 | Recro Pharma Inc （レクロ・ファ―マ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 レクロ・ファーマ（Recro Pharma Inc.）臨床段階の製薬会社である。同社は病院用及び外来ケア施設向けに急性疼痛の治療のための非オピオイド製品の開発に従事する。同社のリード候補製品は、メロキシカムの注射可能な形態である。疼痛適応症の候補製品には、急性術後疼痛の治療のための開発候補製品である注射可能なメロキシカム、術後疼痛の治療のための開発中の製品候補Dex-IN、及び慢性疼痛の治療のための製品候補であるDex-SLとFado(Fadolmidine)が含まれる。Fadoは、手術または特定の種類の慢性疼痛に関連する痛みのために脊椎に注射することによって使用される候補製品であり、糖尿病患者に起こりうる局所組織（神経障害）、特に下肢の神経損傷に関連する重篤な痛みを治療するための局所適用のための製品である。 レクロ・ファ―マは米国の臨床段階の特殊医薬品会社。術後疼痛のための非オピオイド治療薬を開発。主要製品のデックズ-INは、術後疼痛の治療や癌突出痛の治療のための開発中の製品候補で、デックズ-SLは、慢性疼痛の治療のために開発する製品候補。本社はペンシルベニア州。 Recro Pharma Inc. is a contract development and manufacturing organization (CDMO) with capabilities from early feasibility to commercial manufacturing. With an expertise in solving complex manufacturing problems, Recro is a leading CDMO providing oral solid dosage form development, end-to-end regulatory support, clinical and commercial manufacturing, and packaging and logistics services to the global pharmaceutical market. |
| 本社所在地 | 490 Lapp Road Malvern PA 19355 USA |
| 代表者氏名 | Wayne B. Weisman ウェイン・B・ワイズマン |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +1 484-395-2400 |
| 設立年月日 | 39387 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | 2014年 |
| 従業員数 | 256人 |
| url | www.recropharma.com |
| nasdaq_url | https://www.nasdaq.com/symbol/reph |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -42.25000 |
| 終値（lastsale） | 6.965 |
| 時価総額（marketcap） | 144301308.795 |
| 時価総額 | 時価総額（百万ドル） 149.79160 |
| 売上高 | 売上高（百万ドル） 77.43900 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 155.19660 |
| 当期純利益 | 当期純利益（百万ドル） -50.40800 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Recro Pharma Inc revenues increased 16% to $41.3M. Net loss increased 49% to $25.2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Acute Care segment loss increase of 48% to $40M. Basic Earnings per Share excluding Extraordinary Items decreased from -$0.89 to -$1.27. |
REPHのテクニカル分析
REPHのニュース
Recro Reports Inducement Grants for New Staff 2021/07/07 11:00:00 Intrado Digital Media
EXTON, Pa., July 07, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Recro; NASDAQ: REPH ), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for companies developing oral solid dose drug products, today announced the expansion of its team through the addition of new employees to support business development, technical operations and certain strategic initiatives.
Athyrium Capital Management, LP Buys Recro Pharma Inc 2021/06/15 14:38:02 GuruFocus
Related Stocks: REPH ,
Recro Pharma Inc (REPH) falls 5.58% for May 19 2021/05/19 22:00:22 Equities
Recro Pharma Inc (NASDAQ: REPH) shares fell -5.58% to end trading Wednesday at $2.37 per share - a net change of $-0.14. Shares traded between $2.50 and $2.36 throughout the day. 189352 shares of Recro Pharma Inc exchanged hands. Visit Recro Pharma Incs profile for more information. About The Nasdaq Stock Market The Nasdaq Stock Market is a global leader in trading data and services, and equities and options listing. Nasdaq is the world\''s leading exchange for options volume and is home to the five largest US companies - Apple, Microsoft, Amazon, Alphabet and Facebook. To get more information on Recro Pharma Inc and to follow the companys latest updates, you can visit the companys profile page here: Recro Pharma Incs Profile . For more news on the financial markets be sure to visit Equities News . Also, dont forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week. Sources: Chart is provided by TradingView based on 15-minute-delayed prices. All other data is provided by Barchart as of 4:30pm ET on the day of publication.
Mak Capital One Llc Buys Tufin Software Technologies, Recro Pharma Inc, Sells US Foods Holding ... 2021/05/18 23:38:10 GuruFocus
Related Stocks: TUFN , REPH , USFD , ADT , IMMR ,
Recro shares rise on development agreement with Astex Pharmaceuticals 2021/05/18 11:35:56 Seeking Alpha
Mid-Day Market Update: Nasdaq Rises Over 100 Points; Recro Pharma Shares Plummet - Stocks News Feed 2021/02/26 17:17:20 Stocks News Feed
Midway through trading Friday, the Dow traded down 0.69% to 31,184.21 while the NASDAQ rose 0.95% to 13,243.64. The S&P also rose, gaining 0.21% to 3,837.28. The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 28,413,630 cases with around 508,310 deaths. India confirmed a total of… Read More »Mid-Day Market Update: Nasdaq Rises Over 100 Points; Recro Pharma Shares Plummet
Recro Pharma Wall street estimates Earnings report Stock market Insights & financial analysis 2021/02/26 00:39:00 Stock Market Daily
Recro Pharma announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
Recap: Recro Pharma Q3 Earnings 2020/11/09 07:24:00 Benzinga
Shares of Recro Pharma (NASDAQ:REPH) were unchanged after the company reported Q3 results. Quarterly Results Earnings per share increased 52.63% year …
The Daily Biotech Pulse: Aurinia Pulls The Plug On Dry Eye Disease Study, Karyopharm's Positive Readout, Emergency Use Authorization For OraSure 2020/11/03 12:38:06 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 2) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Immunovant Inc (NASDAQ: IMVT ) United Therapeutics Corporation (NASDAQ: UTHR ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Nov. 2) AEterna Zentaris Inc. (NASDAQ: AEZS ) Aikido Pharma Inc (NASDAQ: AIKI ) Artelo Biosciences Inc (NASDAQ: ARTL ) Avita Therapeutics Inc (NASDAQ: RCEL ) Benitec Biopharma Inc (NASDAQ: BNTC ) BioCardia Inc (NASDAQ: BCDA ) Biondvax Pharmaceuticals Ltd – ADR (NASDAQ: BVXV ) Catabasis Pharmaceuticals Inc (NASDAQ: CATB ) Celsion Corporation (NASDAQ: CLSN ) Codiak BioSciences Inc (NASDAQ: CDAK ) Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX ) Entasis Therapeutics Holdings Inc (NASDAQ: ETTX ) FSD Pharma Inc (NASDAQ: HUGE ) Galecto Inc (NASDAQ: GLTO ) (went public Thursday) Hoth Therapeutics Inc (NASDAQ: HOTH ) Inhibrx Inc (NASDAQ: INBX ) Iterum Therapeutics PLC (NASDAQ: ITRM ) Jaguar Health Inc (NASDAQ: JAGX ) Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX ) Monopar Therapeutics Inc (NASDAQ: MNPR ) Nabriva Therapeutics PLC – ADR (NASDAQ: NBRV ) Neovasc Inc (NASDAQ: NVCN ) Neurobo Pharmaceuticals Inc (NASDAQ: NRBO ) Orchard Therapeutics PLC – ADR (NASDAQ: ORTX ) (halted dosing in Strimvelis study after it was linked to the development of leukemia in a patient) Orphazyme A S ADR (NASDAQ: ORPH ) Pliant Therapeutics Inc (NASDAQ: PLRX ) RA Medical Systems Inc (NYSE: RMED ) Recro Pharma Inc (NASDAQ: REPH ) Rockwell Medical Inc (NASDAQ: RMTI ) Teligent Inc (NEW JERSEY) (NASDAQ: TLGT ) Titan Pharmaceuticals, Inc. common stock (NASDAQ: TTNP ) Stocks In Focus Aurinia Ends Dry Eye Disease Study Aurinia Pharmaceuticals Inc (NASDAQ: AUPH ) said topline results from its Phase 2/3 AUDREY clinical study evaluating voclosporin ophthalmic solution for the potential treatment of …
The Daily Biotech Pulse: AbbVie In-licenses I-Mab's Cancer Drug, Savara Pulls The Plug On Cystic Fibrosis Study 2020/09/04 11:28:02 Benzinga
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 3) Akouos Inc (NASDAQ: AKUS ) FibroGen Inc (NASDAQ: FGEN )(reacted to an adverse clinical readout for a rival drug to treat chronic kidney disease related anemia) Generation Bio Co (NASDAQ: GBIO ) Immunovant Inc (NASDAQ: IMVT ) Sutro Biopharma Inc (NASDAQ: STRO ) ( reacted to announcement concerning presentation of positive data for ovarian cancer drug) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 3) Akebia Therapeutics Inc (NASDAQ: AKBA ) (announced negative safety results for a late-stage study of drug to treat chronic kidney disease-induced anemia) AnPac Bio-Medical Science Co Ltd – ADR (NASDAQ: ANPC ) Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC ) Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT ) Genfit SA (NASDAQ: GNFT ) Gritstone Oncology Inc (NASDAQ: GRTS ) Happiness Biotech Group Ltd (NASDAQ: HAPP ) Homology Medicines Inc (NASDAQ: FIXX ) Immatics NV (NASDAQ: IMTX ) Interpace Biosciences Inc (NASDAQ: IDXG ) Jaguar Health Inc (NASDAQ: JAGX ) Legend Biotech Corp (NASDAQ: LEGN ) Monopar Therapeutics Inc (NASDAQ: MNPR ) NanoVibronix Inc (NASDAQ: NAOV ) Odonate Therapeutics Inc (NASDAQ: ODT ) RA Medical Systems Inc (NYSE: RMED ) Recro Pharma Inc (NASDAQ: REPH ) Rockwell Medical Inc (NASDAQ: RMTI ) Soliton Inc (NASDAQ: SOLY ) Sun BioPharma, Inc. (NASDAQ: SNBP ) Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS ) Teligent Inc (NASDAQ: TLGT ) Related Link: Attention Biotech Investors: Mark Your Calendar For September PDUFA Dates Stocks In Focus Lilly Gets FDA Nod For 2 Higher Doses of Its Best-selling Diabetes Drug Eli Lilly And Co (NYSE: LLY ) said the FDA approved two additional doses of its Type 2 diabetes drug Trulicity.